News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
130,807 Results
Type
Article (4503)
Company Profile (88)
Press Release (126216)
Section
Business (42305)
Career Advice (209)
Deals (6194)
Drug Delivery (13)
Drug Development (17855)
Employer Resources (19)
FDA (1522)
Job Trends (2843)
News (66844)
Policy (3690)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 Biotech Bay Standard (1)
Academia (310)
Adcomms (1)
Allergies (16)
Alliances (11531)
ALS (27)
Alzheimer's disease (360)
Antibody-drug conjugate (ADC) (25)
Approvals (1532)
Artificial intelligence (46)
Autoimmune disease (8)
Automation (3)
Bankruptcy (38)
Best Places to Work (2314)
BIOSECURE Act (13)
Biosimilars (6)
Biotechnology (85)
Bladder cancer (19)
Brain cancer (6)
Breast cancer (65)
Cancer (525)
Cardiovascular disease (15)
Career advice (197)
Career pathing (4)
CAR-T (53)
Cell therapy (164)
Cervical cancer (6)
Clinical research (14389)
Collaboration (239)
Compensation (97)
Complete response letters (2)
COVID-19 (439)
CRISPR (7)
C-suite (96)
Cystic fibrosis (26)
Data (564)
Depression (7)
Diabetes (47)
Diagnostics (744)
Digital health (1)
Diversity, equity & inclusion (9)
Drug discovery (42)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12580)
Editorial (4)
Employer resources (19)
Events (24860)
Executive appointments (244)
FDA (1742)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (208)
Gene editing (21)
Generative AI (4)
Gene therapy (81)
GLP-1 (107)
Government (349)
Guidances (9)
Healthcare (1573)
Huntington's disease (12)
IgA nephropathy (6)
Immunology and inflammation (23)
Indications (9)
Infectious disease (465)
Inflammatory bowel disease (51)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (33)
Interviews (17)
IPO (2950)
IRA (4)
Job creations (667)
Job search strategy (185)
Kidney cancer (1)
Labor market (7)
Layoffs (39)
Legal (642)
Liver cancer (12)
Lung cancer (42)
Lymphoma (48)
Management (4)
Manufacturing (77)
MASH (9)
Medical device (401)
Medtech (401)
Mergers & acquisitions (3422)
Metabolic disorders (109)
Multiple sclerosis (21)
NASH (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (3)
Neuroscience (482)
NextGen: Class of 2025 (867)
Non-profit (279)
Northern California (776)
Now hiring (4)
Obesity (56)
Opinion (39)
Ovarian cancer (30)
Pain (19)
Pancreatic cancer (19)
Parkinson's disease (35)
Partnered (4)
Patents (50)
Patient recruitment (26)
Peanut (12)
People (16422)
Pharmaceutical (8)
Phase I (5692)
Phase II (6876)
Phase III (3567)
Pipeline (296)
Podcasts (2)
Policy (23)
Postmarket research (215)
Preclinical (2435)
Press Release (51)
Prostate cancer (18)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (67)
Real estate (1444)
Recruiting (10)
Regulatory (2982)
Reports (13)
Research institute (310)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (12)
Series A (38)
Series B (28)
Service/supplier (2)
Sickle cell disease (12)
Southern California (718)
Special edition (1)
Spinal muscular atrophy (46)
Sponsored (5)
Startups (991)
State (1)
Stomach cancer (2)
Supply chain (13)
The Weekly (2)
United States (5877)
Vaccines (76)
Venture capitalists (7)
Webinars (6)
Weight loss (20)
Women's health (4)
Worklife (2)
Date
Today (41)
Last 7 days (196)
Last 30 days (756)
Last 365 days (9017)
2025 (2186)
2024 (9265)
2023 (10062)
2022 (12179)
2021 (12849)
2020 (9978)
2019 (6780)
2018 (5335)
2017 (6164)
2016 (5692)
2015 (6505)
2014 (4973)
2013 (4086)
2012 (4423)
2011 (4896)
2010 (4538)
Location
Africa (137)
Alabama (27)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (8516)
Australia (1993)
California (1789)
Canada (525)
China (102)
Colorado (29)
Connecticut (63)
Delaware (22)
Europe (18610)
Florida (164)
Georgia (25)
Idaho (10)
Illinois (122)
India (3)
Indiana (91)
Iowa (1)
Japan (32)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (207)
Massachusetts (1303)
Michigan (65)
Minnesota (91)
Missouri (7)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (393)
New Mexico (6)
New York (434)
North Carolina (258)
North Dakota (3)
Northern California (776)
Ohio (37)
Oklahoma (5)
Oregon (4)
Pennsylvania (355)
Puerto Rico (3)
Rhode Island (4)
South America (199)
South Carolina (1)
Southern California (718)
Tennessee (15)
Texas (203)
Utah (20)
Virginia (10)
Washington D.C. (7)
Washington State (305)
Wisconsin (5)
130,807 Results for "allele biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories announced that data from the pivotal Phase 3 ALLELE study of tab-cel, approved in the European Union in adults and children two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease following solid organ transplant or hematopoietic cell transplant, were published for the first time online in The Lancet Oncology.
January 31, 2024
·
9 min read
Drug Development
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences Ltd. today announced positive results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003, which is being developed as a potential disease modifying therapeutic for Huntington’s disease (HD).
June 25, 2024
·
11 min read
Press Releases
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
December 9, 2024
·
7 min read
Press Releases
Momentum Biotechnologies Announces Acquisition of OmicScouts
March 5, 2025
·
4 min read
Drug Development
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces positive 24-month follow-up results from its Phase I/II study evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy for retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene.
May 7, 2024
·
6 min read
Press Releases
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
March 31, 2025
·
1 min read
Press Releases
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
March 26, 2025
·
2 min read
Layoffs
Sana Biotechnology Will Lay Off Employees as It Shifts Pipeline
About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 diabetes program and looks to extend its cash runway.
November 5, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
March 5, 2025
·
2 min read
Press Releases
Anbio Biotechnology Announces Closing of Initial Public Offering
February 21, 2025
·
4 min read
1 of 13,081
Next